Lewis Stuart

2021 - Cymabay Therapeutics

In 2021, Lewis Stuart earned a total compensation of $1.5M as Chief Commercial Officer at Cymabay Therapeutics.

Compensation breakdown

Bonus$20,000
Non-Equity Incentive Plan$100,348
Option Awards$1,153,152
Salary$257,692
Other$750
Total$1,531,942

Stuart received $1.2M in option awards, accounting for 75% of the total pay in 2021.

Stuart also received $20K in bonus, $100.3K in non-equity incentive plan, $257.7K in salary and $750 in other compensation.

Rankings

In 2021, Lewis Stuart's compensation ranked 7,161st out of 12,397 executives tracked by ExecPay. In other words, Stuart earned more than 42.2% of executives.

ClassificationRankingPercentile
All
7,161
out of 12,397
42nd
Division
Manufacturing
3,132
out of 5,492
43rd
Major group
Chemicals And Allied Products
1,383
out of 2,367
42nd
Industry group
Drugs
1,232
out of 2,090
41st
Industry
Pharmaceutical Preparations
901
out of 1,537
41st
Source: SEC filing on April 26, 2022.

Stuart's colleagues

We found four more compensation records of executives who worked with Lewis Stuart at Cymabay Therapeutics in 2021.

2021

Sujal Shah

Cymabay Therapeutics

Chief Executive Officer

2021

Dennis Kim

Cymabay Therapeutics

Chief Medical Officer

2021

Charles McWherter

Cymabay Therapeutics

President of R&D

2021

Paul Quinlan

Cymabay Therapeutics

General Counsel

News

In-depth

You may also like